Case Report: Pembrolizumab-Induced Epiglottitis in Early Triple Negative Breast Cancer
https://doi.org/10.47829/ACMCR.2025.15101 The neoadjuvant use of the immune check point inhibitor (ICI) pembrolizumab has significantly increased the complete pathological response (CPR) rate for early triple negative breast cancer (TNBC). However, pembrolizumab is associated with a variety of immune related adverse events (irAEs).
Case Report: Pembrolizumab-Induced Epiglottitis in Early Triple Negative Breast Cancer Read More »
